Skip to main content
. 2022 Nov 11;12:19323. doi: 10.1038/s41598-022-24103-x

Figure 3.

Figure 3

Empagliflozin alters inflammatory responses after renal I/R injury. (A) Left, Representative images of immunostaining for interleukin-6 (IL-6) in kidney sections after renal I/R injury. Scale bars, 50 μm. Sham sham-operated, I/R ischemia/reperfusion, EMPA empagliflozin. Right, the level of immunoreactivity of IL-6 in mouse kidneys post I/R. Each group, n = 5. (B) Left, Representative blots for IL-6 and GAPDH in mouse kidneys; Right, IL-6/GAPDH ratio after renal I/R injury. n = 4 per group. (C) Left, Representative images of immunostaining for tumor necrosis factor-α (TNF-α) in kidney sections after renal I/R injury. Scale bars, 50 μm. Sham sham-operated, I/R ischemia/reperfusion, EMPA empagliflozin. Right panel, TNF-α immunoreactivity levels in mouse kidneys post I/R. Each group, n = 5. (D) Left, Representative blots for TNF-α and GAPDH in mouse kidneys; Right, TNF-α/GAPDH ratio after renal I/R injury. n = 4 per group. Data shown are the mean ± SD. Significant differences between groups were determined by one-way ANOVA (AD).